IL260981B - The trifluoroacetate salt of the tlr7 agonist type b crystal structure, preparation, and methods of use - Google Patents

The trifluoroacetate salt of the tlr7 agonist type b crystal structure, preparation, and methods of use

Info

Publication number
IL260981B
IL260981B IL260981A IL26098118A IL260981B IL 260981 B IL260981 B IL 260981B IL 260981 A IL260981 A IL 260981A IL 26098118 A IL26098118 A IL 26098118A IL 260981 B IL260981 B IL 260981B
Authority
IL
Israel
Prior art keywords
crystalline form
preparation methods
trifluoroacetate salt
tlr7 agonist
tlr7
Prior art date
Application number
IL260981A
Other languages
English (en)
Hebrew (he)
Inventor
Zhaozhong Ding
Fei Sun
Ling Yang
Yinghu Hu
Yilong Zhou
Zheng Wang
Rui Zhao
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Zhaozhong Ding
Fei Sun
Ling Yang
Yinghu Hu
Yilong Zhou
Zheng Wang
Rui Zhao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Zhaozhong Ding, Fei Sun, Ling Yang, Yinghu Hu, Yilong Zhou, Zheng Wang, Rui Zhao filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of IL260981B publication Critical patent/IL260981B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
IL260981A 2016-02-05 2018-08-05 The trifluoroacetate salt of the tlr7 agonist type b crystal structure, preparation, and methods of use IL260981B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610081899.3A CN107043377A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
PCT/CN2017/072894 WO2017133687A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的三氟乙酸盐、晶型b、制备方法和用途

Publications (1)

Publication Number Publication Date
IL260981B true IL260981B (en) 2022-05-01

Family

ID=59500539

Family Applications (1)

Application Number Title Priority Date Filing Date
IL260981A IL260981B (en) 2016-02-05 2018-08-05 The trifluoroacetate salt of the tlr7 agonist type b crystal structure, preparation, and methods of use

Country Status (23)

Country Link
US (1) US10683296B2 (enExample)
EP (1) EP3412674B1 (enExample)
JP (1) JP6877450B2 (enExample)
KR (1) KR102393281B1 (enExample)
CN (2) CN107043377A (enExample)
AR (1) AR107550A1 (enExample)
AU (1) AU2017214135B2 (enExample)
CA (1) CA3013521C (enExample)
CL (1) CL2018002101A1 (enExample)
DK (1) DK3412674T3 (enExample)
EA (1) EA037048B1 (enExample)
ES (1) ES2834304T3 (enExample)
HU (1) HUE052210T2 (enExample)
IL (1) IL260981B (enExample)
MX (1) MX374300B (enExample)
MY (1) MY198137A (enExample)
NZ (1) NZ745023A (enExample)
PH (1) PH12018501641B1 (enExample)
SG (1) SG11201806688QA (enExample)
TW (1) TWI778952B (enExample)
UA (1) UA121276C2 (enExample)
WO (1) WO2017133687A1 (enExample)
ZA (1) ZA201805240B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
EP3414239A2 (en) 2016-02-05 2018-12-19 Denali Therapeutics Inc. Inhibitors of receptor-interacting protein kinase 1
JP7385602B2 (ja) * 2018-05-25 2023-11-22 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 肺癌を治療するためのtlr7アゴニストおよびその医薬の組み合わせ
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途
CA3170551A1 (en) 2020-03-02 2021-09-10 Yong Taik Lim Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
EP4194010A4 (en) 2020-08-04 2025-03-26 Progeneer Inc. Conjugate of a functional drug and a toll-like receptor 7 or 8 agonist with a temporarily inactivated drug site, and use thereof
EP4194006A4 (en) 2020-08-04 2024-12-04 Progeneer Inc. mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN119431359A (zh) * 2023-07-28 2025-02-14 苏州申拓医药科技有限公司 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
BRPI0923305B1 (pt) 2008-12-09 2019-01-22 Gilead Sciences Inc moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende
CA2826295C (en) * 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
WO2013103967A1 (en) * 2012-01-05 2013-07-11 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
PT2906563T (pt) * 2012-10-10 2018-05-23 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças
EP2922550B1 (en) * 2012-11-20 2017-04-19 Glaxosmithkline LLC Novel compounds
PT3137470T (pt) * 2014-05-01 2021-06-24 Novartis Ag Compostos e composições como agonistas do recetor tipo toll 7
KR20160144399A (ko) * 2014-05-01 2016-12-16 노파르티스 아게 톨-유사 수용체 7 효능제로서의 화합물 및 조성물
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
UA117634C2 (uk) * 2014-08-15 2018-08-27 Чиа Тай Тяньцін Фармасьютикал Ґруп Ко., Лтд. Піролопіримідинові сполуки, що використовуються як агоніст tlr7
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂

Also Published As

Publication number Publication date
CA3013521C (en) 2022-07-12
US20190031666A1 (en) 2019-01-31
EA037048B1 (ru) 2021-01-29
PH12018501641B1 (en) 2021-03-26
EP3412674B1 (en) 2020-09-16
US10683296B2 (en) 2020-06-16
JP6877450B2 (ja) 2021-05-26
AR107550A1 (es) 2018-05-09
MX2018009503A (es) 2018-12-11
ZA201805240B (en) 2024-09-25
HUE052210T2 (hu) 2021-04-28
BR112018015878A2 (pt) 2018-12-26
AU2017214135B2 (en) 2020-08-13
TW201728591A (zh) 2017-08-16
CN108602833A (zh) 2018-09-28
WO2017133687A1 (zh) 2017-08-10
JP2019504103A (ja) 2019-02-14
SG11201806688QA (en) 2018-09-27
PH12018501641A1 (en) 2019-06-03
AU2017214135A1 (en) 2018-08-23
EP3412674A1 (en) 2018-12-12
UA121276C2 (uk) 2020-04-27
EP3412674A4 (en) 2019-07-17
ES2834304T3 (es) 2021-06-17
CA3013521A1 (en) 2017-08-10
HK1259182A1 (zh) 2019-11-29
MY198137A (en) 2023-08-07
CL2018002101A1 (es) 2018-12-07
KR102393281B1 (ko) 2022-05-02
CN108602833B (zh) 2020-07-28
KR20180104118A (ko) 2018-09-19
MX374300B (es) 2025-03-06
EA201891772A1 (ru) 2019-01-31
NZ745023A (en) 2022-09-30
DK3412674T3 (da) 2020-11-09
CN107043377A (zh) 2017-08-15
TWI778952B (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
IL260981B (en) The trifluoroacetate salt of the tlr7 agonist type b crystal structure, preparation, and methods of use
IL260968B (en) Type a crystal structure of trl7 agonist, methods of preparation and its uses
PL3453707T3 (pl) Pochodna benzazepiny, sposób wytwarzania, kompozycja farmaceutyczna i jej zastosowanie
EP3299369A4 (en) Pyrido-azaheterecydic compound and preparation method and use thereof
IL260965B (en) The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structures
SG11201608372PA (en) Irinotecan hydrochloride composite phospholipid composition, preparation method and use thereof
SG11201609405VA (en) Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof
EP3235851A4 (en) Nylon salt and preparation method therefor
IL241038B (en) A new salt of abacinostat, a related crystalline form, a method for their preparation and pharmaceutical preparations containing them
ZA201704743B (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
IL266345A (en) Dihydropyrimidine compound and method of preparation and use thereof
SI3327012T1 (sl) Kristalinične oblike bilastina in postopki za pripravo le-teh
PT3350150T (pt) 1,1-difeniletilenos substituídos por alcenilfenoxilo, processos para a sua preparação e sua utilização
ME03727B (me) Zamjena za so i njena primena
EP3241823A4 (en) Pyrrole amide compound, preparation method therefor, and use thereof
SG11201911936YA (en) Substituted quinolinycyclohexylpropanamide compounds and improved methods for their preparation
RO130539B8 (ro) Compoziţie erbicidă, procedeu de preparare şi utilizarea acesteia
LT3390358T (lt) Kristalinis eravaciklino bis-hidrochloridas
IL254597A0 (en) Crystalline form of ahu377, method for its preparation and use
GB201703316D0 (en) Salts, compositions, their preparation and uses
IL262597B (en) Piperidinyl derivatives, their preparation and use
EP3293179A4 (en) Amide compound and the preparation method and use thereof
PT3140287T (pt) Novo sal de ivabradina e um processo para a sua preparação
IL235077A0 (en) New derivatives of thiochromano[2,3-c]quino lin-12-one, its preparation method and application
SG10201406318YA (en) Novel thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof